Sudeep Pharma Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/h8c2offvao6978yqcouajnjt.pdf

Key Takeaways


Pharma Food & Nutrition: The Volume-Margin Disconnect

Shanil Bhayani: "The quantity volume growth is north of 20% in this category. What we are seeing is for phosphate specifically, the price increase we have only passed on to the customers in Q1. So we have continued to honor the orders in March and April."

Specialty Ingredients: The High-Growth Engine


Battery Materials: The April 2027 Catalyst

Shanil Bhayani: "The goal is not to compete with China. Our focus right from the beginning since we started this business has been to give a product which has, which is highly competitive from a performance perspective against the Chinese iron phosphate because 100% of iron phosphate today is manufactured in China."

Greenfield & NSS: The Capacity and Platform Build-Out


Margins: The Recovery Path

Shanil Bhayani: "From a margin perspective, we will not talk too much today about the battery as well as the new molecules that we bring into market, right? We have to also safeguard our, I mean, not to make everything too public because our suppliers, customers, everyone would have access to this information."

Working Capital & Raw Material Management


Guidance & Commitments

CommitmentSpecificsTimeline
Pharma food & nutrition EBITDA growth~15% growthFY27 and FY28
Overall margin recoveryTrack back to FY24/FY25 levels (37–38% EBITDA)Next couple of quarters
Net working capital daysNormalise to 150–160 daysWithin FY27
Battery materials Phase 1 commissioning25,000 MT capacity onlineApril 2027
Battery materials volume (analyst assumption)~2,500 MT in FY27 called a "fair assumption"FY27
Bisglycinate margin contributionHigher margin contribution beginsStarting FY28
Greenfield customer qualificationsApproval process underway6–12 months depending on product

Key Metrics

MetricQ4 FY26
Revenue from operations₹182.3 cr, +15.7% YoY
EBITDA₹62.6 cr, vs ₹58.8 cr in Q4 FY25
EBITDA margin34.3%
PAT₹48.5 cr, vs ₹44.2 cr in Q4 FY25
Revenue from operations (FY26)₹642.3 cr, +27.9% YoY
EBITDA (FY26)₹221.9 cr, +16.8% YoY
EBITDA margin (FY26)34.6%, vs 37.8% in FY25
PAT (FY26)₹174.3 cr, vs ₹138.7 cr in FY25
Specialty ingredients revenue (FY26)₹280 cr, +62% YoY; 44% of FY26 revenue vs 34% in FY25
Pharma food and nutrition revenue growth (FY26)10% YoY; volume growth north of 20%
Export contribution (FY26)60% of revenue; domestic 40%
New customer approvals (FY26)51, vs FY25
Battery materials purchase orders received~700 metric tons over the last month; 6 customers completed commercial validation
Battery materials Phase 1 capacity25,000 metric tons per year, commissioning by April 2027
Net debt₹33.6 cr as of 31st March 2026; net debt-to-equity 0.04x
Working capital days213 days in FY26, vs 184 days in prior year; targeting 150-160 days in FY27
Inventory increase₹88 cr YoY; raw material +₹41 cr, finished goods +₹37 cr
Gross capex spent (FY26)₹127 cr; SAM land ₹34 cr, greenfield ₹80 cr, maintenance ~₹13 cr
FY27 core business capex outlook~₹25 cr; ~₹10 cr for greenfield completion, ~₹15 cr maintenance
Pharma food and nutrition capacity utilization65% to 70% (without greenfield)
Specialty ingredients capacity utilization35% to 40%
One-time Q4 cost impacts₹3 cr CSR expenditure, ₹1.5 cr higher power and fuel (LPG premium), ₹2 cr air freight impact in selling and distribution